Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
Zacks.com on MSN1d
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.
Vertex Pharmaceuticals Unusual Options Activity
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Zacks.com on MSN6h
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...
Fintel on MSN6d
Wells Fargo Downgrades Vertex Pharmaceuticals (VRTX)
Fintel reports that on January 30, 2025, Wells Fargo downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...
An Investigation Has Commenced on Behalf of Vertex Pharmaceuticals Incorporated Shareholders. Contact Levi & Korsinsky to Discuss your VRTX Losses.
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Vertex Pharmaceuticals’ (VRTX) Outperform Rating Reiterated at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a research note issued to investors on Friday,RTT News ...
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Shares Gap Up on Analyst Upgrade
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) gapped up prior to trading on Friday after Scotiabank raised their price target on the stock from $430.00 to $433.00. The stock had ...